0	9	Induction	Induction	NNP
10	12	of	of	IN
13	21	cytokine	cytokine	NN
22	32	expression	expression	NN
33	35	in	in	IN
36	46	leukocytes	leukocyte	NNS
47	49	by	by	IN
50	57	binding	binding	NN
58	60	of	of	IN
61	80	thrombin-stimulated	thrombin-stimulated	JJ
81	90	platelets	platelet	NNS
90	91	.	.	.

93	103	BACKGROUND	background	NN
103	104	:	:	:
105	114	Activated	activate	VBN
115	124	platelets	platelet	NNS
125	131	tether	tether	VBP
132	135	and	and	CC
136	144	activate	activate	VBP
145	152	myeloid	myeloid	JJ
153	163	leukocytes	leukocyte	NNS
163	164	.	.	.

165	167	To	to	TO
168	179	investigate	investigate	VB
180	183	the	the	DT
184	193	potential	potential	JJ
194	203	relevance	relevance	NN
204	206	of	of	IN
207	211	this	this	DT
212	221	mechanism	mechanism	NN
222	224	in	in	IN
225	230	acute	acute	JJ
231	241	myocardial	myocardial	JJ
242	252	infarction	infarction	NN
253	254	(	(	(
254	257	AMI	AMI	NNP
257	258	)	)	)
258	259	,	,	,
260	262	we	we	PRP
263	271	examined	examine	VBD
272	280	cytokine	cytokine	NN
281	290	induction	induction	NN
291	293	by	by	IN
294	312	leukocyte-platelet	leukocyte-platelet	JJ
313	321	adhesion	adhesion	NN
322	325	and	and	CC
326	329	the	the	DT
330	340	occurrence	occurrence	NN
341	343	of	of	IN
344	362	leukocyte-platelet	leukocyte-platelet	JJ
363	373	conjugates	conjugate	NNS
374	376	in	in	IN
377	385	patients	patient	NNS
386	390	with	with	IN
391	394	AMI	AMI	NNP
394	395	.	.	.

396	403	METHODS	methods	NNS
404	407	AND	and	CC
408	415	RESULTS	results	NNS
415	416	:	:	:
417	419	We	we	PRP
420	428	obtained	obtain	VBD
429	439	peripheral	peripheral	JJ
440	446	venous	venous	JJ
447	452	blood	blood	NN
453	460	samples	sample	NNS
461	463	in	in	IN
464	466	20	20	CD
467	475	patients	patient	NNS
476	480	with	with	IN
481	484	AMI	AMI	NNP
485	491	before	before	IN
492	495	and	and	CC
496	501	daily	daily	RB
502	505	for	for	IN
506	507	5	5	CD
508	512	days	day	NNS
513	518	after	after	IN
519	525	direct	direct	JJ
526	538	percutaneous	percutaneous	JJ
539	551	transluminal	transluminal	JJ
552	560	coronary	coronary	JJ
561	572	angioplasty	angioplasty	NN
573	574	(	(	(
574	578	PTCA	PTCA	NNP
578	579	)	)	)
580	583	and	and	CC
584	586	in	in	IN
587	589	20	20	CD
590	598	patients	patient	NNS
599	609	undergoing	undergo	VBG
610	618	elective	elective	JJ
619	623	PTCA	PTCA	NNP
623	624	.	.	.

625	635	Throughout	throughout	IN
636	639	the	the	DT
640	645	study	study	NN
646	652	period	period	NN
652	653	,	,	,
654	658	CD41	cd41	NN
659	677	immunofluorescence	immunofluorescence	NN
678	680	of	of	IN
681	691	leukocytes	leukocyte	NNS
692	693	(	(	(
693	697	flow	flow	NN
698	707	cytometry	cytometry	NN
707	708	)	)	)
709	717	revealed	reveal	VBD
718	727	increased	increase	VBN
728	746	leukocyte-platelet	leukocyte-platelet	JJ
747	755	adhesion	adhesion	NN
756	758	in	in	IN
759	767	patients	patient	NNS
768	772	with	with	IN
773	776	AMI	AMI	NNP
777	785	compared	compare	VBN
786	790	with	with	IN
791	798	control	control	NN
799	807	patients	patient	NNS
808	809	(	(	(
809	813	mean	mean	NN
814	817	+/-	+/-	CC
818	820	SE	SE	NNP
821	823	of	of	IN
824	836	fluorescence	fluorescence	NN
837	838	[	[	(
838	846	channels	channel	NNS
846	847	]	]	)
848	854	before	before	IN
855	859	PTCA	PTCA	NNP
859	860	:	:	:
861	863	77	77	CD
864	867	+/-	+/-	CC
868	870	16	16	CD
871	877	versus	versus	CC
878	880	35	35	CD
881	884	+/-	+/-	CC
885	886	9	9	CD
886	887	;	;	:
888	889	P	p	NN
890	891	=	=	SYM
892	896	.003	.003	CD
896	897	)	)	)
897	898	.	.	.

899	901	In	in	FW
902	907	vitro	vitro	FW
907	908	,	,	,
909	928	thrombin-stimulated	thrombin-stimulated	JJ
929	934	fixed	fixed	JJ
935	944	platelets	platelet	NNS
945	950	bound	bind	VBD
951	953	to	to	TO
954	965	neutrophils	neutrophil	NNS
966	969	and	and	CC
970	979	monocytes	monocyte	NNS
979	980	.	.	.

981	987	Within	within	IN
988	989	2	2	CD
990	995	hours	hour	NNS
995	996	,	,	,
997	1001	this	this	DT
1002	1010	resulted	result	VBD
1011	1013	in	in	IN
1014	1023	increased	increase	VBN
1024	1028	mRNA	mrna	NN
1029	1032	for	for	IN
1033	1044	interleukin	interleukin	NN
1045	1046	(	(	(
1046	1051	IL),1	il),1	NN
1052	1056	beta	beta	NN
1056	1057	,	,	,
1058	1062	IL-8	il-8	NN
1062	1063	,	,	,
1064	1067	and	and	CC
1068	1076	monocyte	monocyte	NN
1077	1092	chemoattractant	chemoattractant	NN
1093	1100	protein	protein	NN
1101	1102	(	(	(
1102	1108	MCP)-1	mcp)-1	NN
1109	1111	in	in	IN
1112	1126	unfractionated	unfractionated	JJ
1127	1137	leukocytes	leukocyte	NNS
1137	1138	.	.	.

1139	1144	After	after	IN
1145	1146	4	4	CD
1147	1152	hours	hour	NNS
1152	1153	,	,	,
1154	1158	IL-1	il-1	NN
1159	1163	beta	beta	NN
1164	1167	and	and	CC
1168	1172	IL-8	il-8	NN
1173	1186	concentration	concentration	NN
1187	1189	of	of	IN
1190	1193	the	the	DT
1194	1203	cell-free	cell-free	JJ
1204	1215	supernatant	supernatant	NN
1216	1219	had	have	VBD
1220	1229	increased	increase	VBN
1230	1232	by	by	IN
1233	1236	268	268	CD
1237	1240	+/-	+/-	CC
1241	1243	36	36	CD
1243	1244	%	%	NN
1245	1248	and	and	CC
1249	1252	210	210	CD
1253	1256	+/-	+/-	SYM
1257	1258	7	7	CD
1258	1259	%	%	NN
1259	1260	,	,	,
1261	1273	respectively	respectively	RB
1273	1274	,	,	,
1275	1278	and	and	CC
1279	1287	cellular	cellular	JJ
1288	1293	MCP-1	mcp-1	NN
1294	1301	content	content	NN
1302	1305	had	have	VBD
1306	1315	increased	increase	VBN
1316	1318	by	by	IN
1319	1322	170	170	CD
1323	1326	+/-	+/-	SYM
1327	1328	8	8	CD
1328	1329	%	%	NN
1329	1330	.	.	.

1331	1339	Addition	addition	NN
1340	1342	of	of	IN
1343	1352	activated	activate	VBN
1353	1362	platelets	platelet	NNS
1363	1365	to	to	TO
1366	1374	adherent	adherent	JJ
1375	1384	monocytes	monocyte	NNS
1385	1388	had	have	VBD
1389	1390	a	a	DT
1391	1398	similar	similar	JJ
1399	1405	effect	effect	NN
1406	1409	and	and	CC
1410	1413	was	be	VBD
1414	1424	associated	associate	VBN
1425	1429	with	with	IN
1430	1437	nuclear	nuclear	JJ
1438	1450	factor-kappa	factor-kappa	NN
1451	1452	B	B	NNP
1453	1463	activation	activation	NN
1463	1464	.	.	.

1465	1475	Inhibition	Inhibition	NNP
1476	1478	of	of	IN
1479	1486	binding	binding	NN
1487	1489	by	by	IN
1490	1496	anti-P	anti-p	JJ
1497	1505	selectin	selectin	NN
1506	1516	antibodies	antibody	NNS
1517	1524	reduced	reduce	VBD
1525	1528	the	the	DT
1529	1535	effect	effect	NN
1536	1538	of	of	IN
1539	1548	activated	activate	VBN
1549	1558	platelets	platelet	NNS
1559	1561	on	on	IN
1562	1570	cytokine	cytokine	NN
1571	1581	production	production	NN
1581	1582	.	.	.

1583	1594	CONCLUSIONS	conclusions	NNS
1594	1595	:	:	:
1596	1598	In	in	IN
1599	1607	patients	patient	NNS
1608	1612	with	with	IN
1613	1616	AMI	AMI	NNP
1616	1617	,	,	,
1618	1636	leukocyte-platelet	leukocyte-platelet	JJ
1637	1645	adhesion	adhesion	NN
1646	1648	is	be	VBZ
1649	1658	increased	increase	VBN
1658	1659	.	.	.

1660	1667	Binding	binding	NN
1668	1670	of	of	IN
1671	1680	activated	activate	VBN
1681	1690	platelets	platelet	NNS
1691	1698	induces	induce	VBZ
1699	1703	IL-1	il-1	NN
1704	1708	beta	beta	NN
1708	1709	,	,	,
1710	1714	IL-8	il-8	NN
1714	1715	,	,	,
1716	1719	and	and	CC
1720	1725	MCP-1	mcp-1	NN
1726	1728	in	in	IN
1729	1739	leukocytes	leukocyte	NNS
1739	1740	.	.	.

1741	1744	Our	our	PRP$
1745	1753	findings	finding	NNS
1754	1761	suggest	suggest	VBP
1762	1766	that	that	IN
1767	1785	leukocyte-platelet	leukocyte-platelet	JJ
1786	1794	adhesion	adhesion	NN
1795	1806	contributes	contribute	VBZ
1807	1809	to	to	TO
1810	1813	the	the	DT
1814	1824	regulation	regulation	NN
1825	1827	of	of	IN
1828	1840	inflammatory	inflammatory	JJ
1841	1850	responses	response	NNS
1851	1853	in	in	IN
1854	1857	AMI	AMI	NNP
1857	1858	.	.	.